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blood-stage IFA. The European Vaccine Initiative provides project
management and coordination expertise. The PATH Malaria Vac-etter to the Editor
owards validated assays for key immunological outcomes in
alaria vaccine development
A ﬁrst generation partially effective malaria vaccine, RTS,
/AS01, is scheduled to complete an ongoing Phase 3 trial in 2014.
ntense efforts are underway to develop highly effective second
eneration malaria vaccines in accordance with the malaria vac-
ine technology roadmap [1]. An important aspect of this second
eneration development work is agreement on the key immuno-
ogical outcomes for upcoming malaria vaccine trials, and agreed
pproaches on standardised measurement of these outcomes.
The protective mechanisms underlying immunity induced by
alaria vaccines are not fully characterised and are distinct
rom those responsible for naturally acquired immunity. Vaccine-
nduced immune mechanisms are thought to differ according to
ife-cycle target stage for subunit vaccines. Over 30malaria vaccine
rojects are under clinical evaluation or progressing towards the
linic [2]. Of these, about two-thirds have used IgG-based assays for
mmunogenicity, with the other third using T-cell based assays as
he primary immunological readout. In most cases the immunoas-
ays are used as a measure of immunogenicity of the vaccines as
mmune correlates of protection are not known. It is important to
e able to accurately and reproducibly quantify whether desired
mmune responses have been induced. Whatever assay is used,
omparison between immunogenicity of alternate formulations,
djuvants and platforms requires the availability of robust assays.
Harmonisation” of assays refers to use of consensus SOPs between
etworks of laboratories. “Standardization” is a further step which
equires agreed-upon SOPs, reagents and equipment and implies
onﬁrmation that equivalent results will be obtained at different
enters by different operators. “Validation” is a regulatory require-
ent for use of immunoassaydata for licensure purposes and refers
o a stringent quantiﬁcation of assay performance including accu-
acy and reproducibility.
If themalaria vaccineﬁeld is toprogress to the stagewhere assay
esults are known to correlate with vaccine efﬁcacy and are com-
arable between laboratories and in different settings, progress
n the above activities is desirable for key assays. It is also nec-
ssary to develop robust assays with quantiﬁed inter-laboratory
ariability in order to have conﬁdence in down-selection decisions
or progression into pre-clinical development pathways. Substan-
ial funding is required for GMP manufacturing, GLP toxicology
nd regulatory submission; down-selection often rests on assay-
ased comparisons between platforms, adjuvants and antigenic
onstructs. The process of assay harmonization is underway in the
alaria vaccine ﬁeld [3], though a great deal of furtherworkwill be
equired before rational decision-making will be possible based on
tandardized key immunological outcomes (see Fig. 1). The assay
lasses thought to be of greatest relevance to immune protection
re listed in Fig. 2.
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Open access under CC BY-NC-ND license.Fig. 1. Malaria vaccine assay harmonization.
Pre-erythrocytic malaria vaccine development beneﬁts from
the availability of a well developed clinical challenge trial. How-
ever immunological down-selection for progression to the clinic
is based on non-harmonized pre-clinical IgG and T-cell based
assays as well as pre-clinical challenge data. There are no well
developed functional assays in the pre-erythrocytic area, making
assay development is this area one of the priorities. There is good
evidence for protective immunity through cellular responses in
malaria, targeted at liver-stage antigens, but also for blood-stage
antigens in different models. Both enzyme-linked immunospot
(ELISpot) and intracellular cytokine staining (ICS) assays have
been identiﬁed for harmonization on this basis. In the blood-stage
ﬁeld there are two functional assays of note: growth inhibition
(GIA) and antibody-dependent cellular inhibition (ADCI) assays.
Investigators proﬁcient in GIA have participated in several har-
monization efforts resulting in conformity in some aspects of the
assay procedure, and selection and support of one intramural
NIAID laboratory as a PATH MVI Reference center [3–5]. ADCI is
more difﬁcult to standardize, but has the advantage of requiring
far lower IgG concentrations for activity [6] and has therefore been
identiﬁed for harmonization, with the anticipation that this will
be challenging. A PATH MVI ELISA Reference laboratory is funded
for the performance of both blood-stage and pre-erythrocytic
stage ELISAs at the Walter Reed Army Institute of Research
(WRAIR).
In the spirit of growing coordination and collaboration between
groups of funders and scientists, the OPTIMALVAC assay harmo-
nization activity has been initiated (www.optimalvac.eu). This is
a European Union funded project whereby funds have been allo-
cated to harmonize the following assays: ICS, ELISpot, ADCI andcine Initiative is closely involved with the project both through its
steering committee and through targeted, complementary fund-
ing of certain components. PATH MVI also supports the NIAID GIA
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[Fig. 2. Key imm
eference Center as well as the WRAIR ELISA Reference Center
long with USAID support. WHO Initiative for Vaccine Research
IVR) acts to identify and synergize other malaria vaccine assay
armonization activities with OPTIMALVAC and to link with other
isease areas where appropriate.
PATH MVI is, in parallel, conducting comparisons of alternate
re-erythrocytic functional assays and assays of infectivity for sex-
al stage and mosquito antigen vaccine research. Thus, though
hoice of immunological outcomes is complex in malaria vaccina-
ion, a great deal of progress is being made. In the medium term,
onsensus harmonized SOPs should be available for the commu-
ity and identiﬁcation of laboratories with an interest in serving
s additional central testing centers may be facilitated. There are
urrently no WHO designated reference centers. Ultimately a par-
icular assay may progress to the stage where it has met the
equirements of aWHO reference center and where establishment
f such a center is appropriate and feasible in the malaria vaccine
eld.
To conclude, many different approaches to malaria vaccination
re under clinical or advanced pre-clinical evaluation. Comparison
f immunogenicityusing robust standardizedassayswill beamajor
eneﬁt for rational development decision-making, identiﬁcation of
orrelates, andmore rapid and focused product/candidate/concept
dvancement.Where partial clinical efﬁcacy is demonstrated avail-
bility of standardised assay data will maximise the chances of
dentiﬁcation of correlates of protection which can then be used
o iteratively improve vaccine efﬁcacy. Where efﬁcacy is absent,
onﬁdence in immunological outcome data is equally impor-
ant to allow developers to make conclusions about whether
he vaccine concept has been tested to failure and can thus be
onﬁdently terminated. A coordinated multilateral approach to
ssay harmonization, standardization and identiﬁcation of central
esting centers is underway and will be critical for the devel-
pment of a highly effective second generation malaria vaccine.
any in the malaria R&D arena feel that such a vaccine will
e necessary if malaria transmission is to be successfully inter-
upted in high malaria transmission settings. Thus the drive
owards validated assays for immunological outcomes in malaria
accination may prove vital if malaria is ever to be eradicated
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